Transnasal humidified rapid insufflation ventilatory exchange for oxygenation of children during apnoea: a prospective randomised controlled trial.
Options
BORIS DOI
Date of Publication
March 2018
Publication Type
Article
Division/Institute
Author
Subject(s)
Series
British journal of anaesthesia
ISSN or ISBN (if monograph)
0007-0912
Publisher
Elsevier
Language
English
Publisher DOI
PubMed ID
29452816
Uncontrolled Keywords
Description
BACKGROUND
Transnasal humidified rapid insufflation ventilatory exchange (THRIVE) comprises the administration of heated, humidified, and blended air/oxygen mixtures via nasal cannula at rates of ≥2 litres kg min. The aim of this randomized controlled study was to evaluate the length of the safe apnoea time using THRIVE with two different oxygen concentrations (100% vs 30% oxygen) compared with standard low-flow 100% oxygen administration.
METHODS
Sixty patients, aged 1-6 yr, weighing 10-20 kg, undergoing general anaesthesia for elective surgery, were randomly allocated to receive one of the following oxygen administration methods during apnoea: 1) low-flow 100% oxygen at 0.2 litres kg min; 2) THRIVE 100% oxygen at 2 litres kg min; and 3) THRIVE 30% oxygen at 2 litres kg min. Primary outcome was time to desaturation to 95%. Termination criteria included SpOdecreased to 95%, transcutaneous COincreased to 65 mmHg, or apnoea time of 10 min.
RESULTS
The median (interquartile range) [range] apnoea time was 6.9 (5.7-7.8) [2.8-10.0] min for low-flow 100% oxygen, 7.6 (6.2-9.1) [5.2-10.0] min for THRIVE 100% oxygen, and 3.0 (2.4-3.7) [0.2-5.3] min for THRIVE 30% oxygen. No significant difference was detected between apnoea times with low-flow and THRIVE 100% oxygen administration (P=0.15). THRIVE with 30% oxygen demonstrated significantly shorter apnoea times (P<0.001) than both 100% oxygen modalities. The overall rate of transcutaneous COincrease was 0.57 (0.49-0.63) [0.29-8.92] kPa minwithout differences between the 3 groups (P=0.25).
CONCLUSIONS
High-flow 100% oxygen (2 litres kg min) administered via nasal cannulas did not extend the safe apnoea time for children weighing 10-20 kg compared with low-flow nasal cannula oxygen (0.2 litres kg min). No ventilatory effect was observed with THRIVE at 2.0 litres kg min.
CLINICAL TRIAL REGISTRATION
NCT02979067.
Transnasal humidified rapid insufflation ventilatory exchange (THRIVE) comprises the administration of heated, humidified, and blended air/oxygen mixtures via nasal cannula at rates of ≥2 litres kg min. The aim of this randomized controlled study was to evaluate the length of the safe apnoea time using THRIVE with two different oxygen concentrations (100% vs 30% oxygen) compared with standard low-flow 100% oxygen administration.
METHODS
Sixty patients, aged 1-6 yr, weighing 10-20 kg, undergoing general anaesthesia for elective surgery, were randomly allocated to receive one of the following oxygen administration methods during apnoea: 1) low-flow 100% oxygen at 0.2 litres kg min; 2) THRIVE 100% oxygen at 2 litres kg min; and 3) THRIVE 30% oxygen at 2 litres kg min. Primary outcome was time to desaturation to 95%. Termination criteria included SpOdecreased to 95%, transcutaneous COincreased to 65 mmHg, or apnoea time of 10 min.
RESULTS
The median (interquartile range) [range] apnoea time was 6.9 (5.7-7.8) [2.8-10.0] min for low-flow 100% oxygen, 7.6 (6.2-9.1) [5.2-10.0] min for THRIVE 100% oxygen, and 3.0 (2.4-3.7) [0.2-5.3] min for THRIVE 30% oxygen. No significant difference was detected between apnoea times with low-flow and THRIVE 100% oxygen administration (P=0.15). THRIVE with 30% oxygen demonstrated significantly shorter apnoea times (P<0.001) than both 100% oxygen modalities. The overall rate of transcutaneous COincrease was 0.57 (0.49-0.63) [0.29-8.92] kPa minwithout differences between the 3 groups (P=0.25).
CONCLUSIONS
High-flow 100% oxygen (2 litres kg min) administered via nasal cannulas did not extend the safe apnoea time for children weighing 10-20 kg compared with low-flow nasal cannula oxygen (0.2 litres kg min). No ventilatory effect was observed with THRIVE at 2.0 litres kg min.
CLINICAL TRIAL REGISTRATION
NCT02979067.
File(s)
File | File Type | Format | Size | License | Publisher/Copright statement | Content | |
---|---|---|---|---|---|---|---|
PIIS0007091217542063.pdf | text | Adobe PDF | 503.44 KB | publisher | published |